SHINE Technologies, headquartered in Janesville, Wisconsin, has raised $240.0 million in new funding from investors. The company is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency, and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing, and fusion material research. It has also commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer, as well as cancer therapy.
This significant capital infusion underscores investor confidence in SHINE's commercially driven approach to deep-tech and its multi-faceted applications of fusion technology. The funds are earmarked to accelerate SHINE's strategic growth initiatives, further scale its commercial operations, and advance its proprietary fusion-based technologies. This investment will support the expansion of its existing commercial operations and the continued development of its innovative solutions. Beyond its current applications, SHINE is pioneering nuclear waste recycling to enhance the sustainability of nuclear energy.
The company's long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike some other fusion companies, SHINE takes a commercially driven path, mirroring successful deep-tech industries. Through this visionary approach, SHINE aims to make a lasting impact across technology, healthcare, and sustainable energy sectors. This investment positions SHINE to continue its expansion and further its mission to deliver innovative solutions that advance technology, healthcare, and sustainable energy.
